Burden of illness associated with sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation
- PMID: 28562132
- DOI: 10.1080/13696998.2017.1336623
Burden of illness associated with sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation
Abstract
Aims: Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of hematopoietic stem cell transplantation (HSCT) associated with significant morbidity and mortality. Healthcare utilization, costs, and mortality were assessed in HSCT patients diagnosed with SOS, with and without multi-organ dysfunction (MOD).
Materials and methods: This retrospective observational study identified real-world patients undergoing HSCT between January 1, 2009 and May 31, 2014 using the Premier Healthcare Database. In absence of a formal ICD-9-CM diagnostic code, SOS patients were identified using a pre-specified definition adapted from Baltimore and Seattle criteria and clinical practice. Severe SOS (SOS/MOD) and non-severe SOS (SOS/no-MOD) were classified according to clinical evidence for MOD in the database.
Results: Of the 5,418 patients with a discharge diagnosis of HSCT, 291 had SOS, with 134 categorized as SOS/MOD and 157 as SOS/no-MOD. The remaining 5,127 patients had HSCT without SOS. Overall SOS incidence was 5.4%, with 46% having evidence of MOD. Distribution of age, gender, and race were similar between the SOS cohorts and non-SOS patients. After controlling for hospital profile and admission characteristics, demographics, and clinical characteristics, the adjusted mean LOS was 31.0 days in SOS/MOD compared to 23.9 days in the non-SOS cohort (medians = 26.9 days vs 20.8 days, p < .001). The adjusted mean cost of SOS/MOD patients was $140,653, which was $41,702 higher than the non-SOS cohort (medians = $105,749 vs $74,395, p < .001). An almost 6-fold increased odds of inpatient mortality was associated with SOS/MOD compared to the non-SOS cohort (odds ratio = 5.88; 95% CI = 3.45-10.33).
Limitations: Limitations of retrospective observational studies apply, since the study was not randomized. Definition for SOS was based on ICD-9 diagnosis codes from a hospital administrative database and reliant on completeness and accuracy of coding.
Conclusions: Analysis of real-world data shows that SOS/MOD is associated with significant increases in healthcare utilization, costs, and inpatient mortality.
Keywords: 30-day readmissions; Burden of illness; Costs; Healthcare resource utilization; Hematopoietic stem cell transplantation (HSCT); Hepatic veno-occlusive disease (VOD); Hospital length of stay; Inpatient mortality; Multi-organ dysfunction; Sinusoidal obstruction syndrome (SOS).
Similar articles
-
Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.Biol Blood Marrow Transplant. 2017 Jun;23(6):997-1004. doi: 10.1016/j.bbmt.2017.03.008. Epub 2017 Mar 8. Biol Blood Marrow Transplant. 2017. PMID: 28285079
-
Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Study on Behalf of the Spanish Hematopoietic Stem Cell Transplantation and Cellular Therapy Group (GETH).Transplant Cell Ther. 2024 Sep;30(9):914.e1-914.e8. doi: 10.1016/j.jtct.2024.06.003. Epub 2024 Jun 7. Transplant Cell Ther. 2024. PMID: 38851323
-
Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.Br J Haematol. 2018 Jun;181(6):816-827. doi: 10.1111/bjh.15267. Epub 2018 May 16. Br J Haematol. 2018. PMID: 29767845 Free PMC article. Clinical Trial.
-
Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.Expert Rev Clin Pharmacol. 2018 Feb;11(2):113-124. doi: 10.1080/17512433.2018.1421943. Epub 2018 Jan 5. Expert Rev Clin Pharmacol. 2018. PMID: 29301447 Review.
-
The use of defibrotide in blood and marrow transplantation.Blood Adv. 2018 Jun 26;2(12):1495-1509. doi: 10.1182/bloodadvances.2017008375. Blood Adv. 2018. PMID: 29945939 Free PMC article. Review.
Cited by
-
Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant.Clinicoecon Outcomes Res. 2018 Dec 17;11:13-22. doi: 10.2147/CEOR.S184883. eCollection 2019. Clinicoecon Outcomes Res. 2018. PMID: 30588050 Free PMC article.
-
Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease.Eur J Health Econ. 2021 Feb;22(1):169-180. doi: 10.1007/s10198-020-01249-x. Epub 2020 Dec 4. Eur J Health Econ. 2021. PMID: 33275188 Free PMC article.
-
Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the "Gruppo Italiano Trapianto di Midollo Osseo".Support Care Cancer. 2020 Nov;28(11):5125-5137. doi: 10.1007/s00520-020-05353-9. Epub 2020 Feb 13. Support Care Cancer. 2020. PMID: 32056012
-
Introduction of new pediatric EBMT criteria for VOD diagnosis: is it time-saving or money-wasting? : Prospective evaluation of pediatric EBMT criteria for VOD.Bone Marrow Transplant. 2020 Nov;55(11):2138-2146. doi: 10.1038/s41409-020-0918-1. Epub 2020 May 12. Bone Marrow Transplant. 2020. PMID: 32398785
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources